Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$4.01 - $12.34 $168 - $518
-42 Reduced 7.04%
555 $2,000
Q2 2022

Aug 12, 2022

BUY
$8.27 - $18.43 $2,588 - $5,768
313 Added 110.21%
597 $7,000
Q1 2022

May 12, 2022

BUY
$12.54 - $46.93 $3,561 - $13,328
284 New
284 $5,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $130M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Ci Investments Inc. Portfolio

Follow Ci Investments Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ci Investments Inc. with notifications on news.